Experience

Energie Côté Sud

• France
• Construction
• 1 - 100 Employee

• Président-directeur général

  • Mar 2014 - Present

• Directeur Général

  • Sep 2007 - Present


APM - Association Progrès du Management
• France
• Professional Training and Coaching
• 100 - 200 Employee
• APM

  • Sep 2017 - Present


AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientist

  • Sep 2005 - Sep 2006

  Development of DMPK oriented QSAR methods. Main Project • Situation: Suggesting new pharmaceutical compounds in lead optimization. • Goals: Identify the required chemical modifications to bring to a compound to improve its physico-chemical / biological properties. • Actions: Extraction/categorisation of experimental data (~50,000 compounds). Identification of existing side-chains replacements (~900,000 substitutions). Calculation of the associated experimental changes. Storage… Show more Development of DMPK oriented QSAR methods. Main Project • Situation: Suggesting new pharmaceutical compounds in lead optimization. • Goals: Identify the required chemical modifications to bring to a compound to improve its physico-chemical / biological properties. • Actions: Extraction/categorisation of experimental data (~50,000 compounds). Identification of existing side-chains replacements (~900,000 substitutions). Calculation of the associated experimental changes. Storage of information in a MySQL database. • Results: Implementation of a substitution database and its web interface that can be queried directly by medicinal chemists. Suggestion of new compounds with the properties wished by the users. Drug Discovery • Interaction with medicinal chemists in oncology project as a modeller. • Analysis of projects data, SAR. Creation of models (PLS, Bayesian Neural Networks). Show less Development of DMPK oriented QSAR methods. Main Project • Situation: Suggesting new pharmaceutical compounds in lead optimization. • Goals: Identify the required chemical modifications to bring to a compound to improve its physico-chemical / biological properties. • Actions: Extraction/categorisation of experimental data (~50,000 compounds). Identification of existing side-chains replacements (~900,000 substitutions). Calculation of the associated experimental changes. Storage… Show more Development of DMPK oriented QSAR methods. Main Project • Situation: Suggesting new pharmaceutical compounds in lead optimization. • Goals: Identify the required chemical modifications to bring to a compound to improve its physico-chemical / biological properties. • Actions: Extraction/categorisation of experimental data (~50,000 compounds). Identification of existing side-chains replacements (~900,000 substitutions). Calculation of the associated experimental changes. Storage of information in a MySQL database. • Results: Implementation of a substitution database and its web interface that can be queried directly by medicinal chemists. Suggestion of new compounds with the properties wished by the users. Drug Discovery • Interaction with medicinal chemists in oncology project as a modeller. • Analysis of projects data, SAR. Creation of models (PLS, Bayesian Neural Networks). Show less



CEA - Commissariat à l'énergie atomique et aux énergies alternatives

• Scientist

  • Oct 2003 - Sep 2005

  French atomic energy centre, life science division. in silico study of ABC transporters (MsbA/P-gp). Group of Dr. S. Orlowski. • Situation: P-gp plays a key-role in multi-drug resistance especially in chemotherapies. • Goals: Investigate the biological relevance of the open-state MsbA structure in a membrane. • Actions: Homology modelling and molecular dynamics simulations (~90,000 atoms). • Results: Demonstrated that the open-state MsbA (PDB: 1JSQ) is biologically relevant… Show more French atomic energy centre, life science division. in silico study of ABC transporters (MsbA/P-gp). Group of Dr. S. Orlowski. • Situation: P-gp plays a key-role in multi-drug resistance especially in chemotherapies. • Goals: Investigate the biological relevance of the open-state MsbA structure in a membrane. • Actions: Homology modelling and molecular dynamics simulations (~90,000 atoms). • Results: Demonstrated that the open-state MsbA (PDB: 1JSQ) is biologically relevant. Highlighted the importance of key residues for the interaction with the membrane / assembly stabilisation. Show less French atomic energy centre, life science division. in silico study of ABC transporters (MsbA/P-gp). Group of Dr. S. Orlowski. • Situation: P-gp plays a key-role in multi-drug resistance especially in chemotherapies. • Goals: Investigate the biological relevance of the open-state MsbA structure in a membrane. • Actions: Homology modelling and molecular dynamics simulations (~90,000 atoms). • Results: Demonstrated that the open-state MsbA (PDB: 1JSQ) is biologically relevant… Show more French atomic energy centre, life science division. in silico study of ABC transporters (MsbA/P-gp). Group of Dr. S. Orlowski. • Situation: P-gp plays a key-role in multi-drug resistance especially in chemotherapies. • Goals: Investigate the biological relevance of the open-state MsbA structure in a membrane. • Actions: Homology modelling and molecular dynamics simulations (~90,000 atoms). • Results: Demonstrated that the open-state MsbA (PDB: 1JSQ) is biologically relevant. Highlighted the importance of key residues for the interaction with the membrane / assembly stabilisation. Show less



University of Southampton

• United Kingdom
• Higher Education
• 700 & Above Employee

• PhD

  • Oct 1999 - Sep 2003

  Industrial award from Novartis Pharma U.K. Group of Pr. J.W. Essex. • Situation: Development of orally available compounds requires an estimation of their permeability. • Goals: Develop a simplified membrane model. Calculate permeability in silico. • Actions: Creation of a molecular dynamics code based on the Gay-Berne potential. • Results: Development of a simplified model faster than a conventional model (atomistic), while giving access to information at the atomic level… Show more Industrial award from Novartis Pharma U.K. Group of Pr. J.W. Essex. • Situation: Development of orally available compounds requires an estimation of their permeability. • Goals: Develop a simplified membrane model. Calculate permeability in silico. • Actions: Creation of a molecular dynamics code based on the Gay-Berne potential. • Results: Development of a simplified model faster than a conventional model (atomistic), while giving access to information at the atomic level. Application to the calculation of permeability of small chemicals (bioavailability). Show less Industrial award from Novartis Pharma U.K. Group of Pr. J.W. Essex. • Situation: Development of orally available compounds requires an estimation of their permeability. • Goals: Develop a simplified membrane model. Calculate permeability in silico. • Actions: Creation of a molecular dynamics code based on the Gay-Berne potential. • Results: Development of a simplified model faster than a conventional model (atomistic), while giving access to information at the atomic level… Show more Industrial award from Novartis Pharma U.K. Group of Pr. J.W. Essex. • Situation: Development of orally available compounds requires an estimation of their permeability. • Goals: Develop a simplified membrane model. Calculate permeability in silico. • Actions: Creation of a molecular dynamics code based on the Gay-Berne potential. • Results: Development of a simplified model faster than a conventional model (atomistic), while giving access to information at the atomic level. Application to the calculation of permeability of small chemicals (bioavailability). Show less


Quest
• Morocco
• Professional Services
• 1 - 100 Employee
• scientist

  • 1998 - 1998